These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33593826)

  • 21. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma.
    Song L; Chen Y; Ding J; Wu H; Zhang W; Ma M; Zang F; Wang Z; Gu N; Zhang Y
    J Mater Chem B; 2020 Feb; 8(5):895-907. PubMed ID: 31909406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Hematopoietic Stem Cell Engrafted IL-15 Transgenic NSG Mice Support Robust NK Cell Responses and Sustained HIV-1 Infection.
    Abeynaike SA; Huynh TR; Mehmood A; Kim T; Frank K; Gao K; Zalfa C; Gandarilla A; Shultz L; Paust S
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
    Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
    Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
    Barve A; Casson L; Krem M; Wunderlich M; Mulloy JC; Beverly LJ
    Exp Hematol; 2018 Nov; 67():18-31. PubMed ID: 30125602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
    Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
    J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.
    Chadalavada D; Adamson TW; Burnett JC; Chen RW; Rossi JJ
    Comp Med; 2014 Jun; 64(3):179-85. PubMed ID: 24956209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
    Laing ST; Griffey SM; Moreno ME; Stoddart CA
    J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.
    Chu Y; Awasthi A; Lee S; Edani D; Yin C; Hochberg J; Shah T; Chung TH; Ayello J; van de Ven C; Klein C; Lee D; Cairo MS
    Oncotarget; 2020 Aug; 11(32):3035-3047. PubMed ID: 32850008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
    Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
    Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.
    Bility MT; Cheng L; Zhang Z; Luan Y; Li F; Chi L; Zhang L; Tu Z; Gao Y; Fu Y; Niu J; Wang F; Su L
    PLoS Pathog; 2014 Mar; 10(3):e1004032. PubMed ID: 24651854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
    Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
    Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.
    Karalis JD; Yoon LY; Hammer STG; Hong C; Zhu M; Nassour I; Ju MR; Xiao S; Castro-Dubon EC; Agrawal D; Suarez J; Reznik SI; Mansour JC; Polanco PM; Yopp AC; Zeh HJ; Hwang TH; Zhu H; Porembka MR; Wang SC
    J Transl Med; 2022 Mar; 20(1):116. PubMed ID: 35255940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.
    Bertolini F; Fusetti L; Mancuso P; Gobbi A; Corsini C; Ferrucci PF; Martinelli G; Pruneri G
    Blood; 2000 Jul; 96(1):282-7. PubMed ID: 10891463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
    Verma B; Wesa A
    Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
    Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
    J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.